Yahoo / Market Guide - AVI BioPharma, Inc.

·	Insider and 5%+ Owners: 35%
·	Over the last 6 months: · one insider sell; 61.0K shares (0.7% of insider shares)
·	Institutional: 5% (8% of float) (33 institutions)
·	Net Inst. Buying: 337.0K shares (+22.83%) (prior quarter to latest quarter)

More From Market Guide

·Highlights
·Performance
·Ratio Comparisons

Business Summary

AVI BioPharma, Inc. (AVI) is a development-stage biopharmaceutical company focusing on developing therapeutic products using two distinct platform technologies, Cancer Immunotheraphy and Gene-targeted drugs, called New-Genes. The Company's principal focus is developing treatments for life-threatening diseases, specifically cancer and heart disease. The Company's two platforms are specially aimed at solving the challenges faced by pharmaceutical products. AVI's therapeutic cancer vaccine, Avicine, which is in clinical trials, is designed to produce an immune response against human chorionic gonadotropin (hCG). hCG is a hormone produced during pregnancy that plays a variety of roles in fostering the development of a fetus, and has also been found in most cancers. The Company has completed the pre-clinical development of two Neu-Gene agents, Resten-NG and Oncomyc-NG, and has filed New Drug Applications with the Food and Drug Administration.

More from Market Guide: Expanded Business Description

Financial Summary

AVI BioPharma, Inc. is a biopharmaceutical company that develops therapeutic products using Cancer immunotherapy and gene-targeted drugs. For the six months ended 6/30/01, revenues fell 91% to $103 thousand. Net loss rose 69% to $6.7 million. Revenues reflect the absence of a $1 million grant for expansion of a license for diagnostic applications. Higher loss reflects increased R&D staffing and expenses associated with clinical testing.

More from Market Guide: Significant Developments

Officers

[Insider Trade Data]

	FY2000 Compensation
	Pay	Exer

Denis Burger, Ph.D, 57 Chairman, CEO	$272K	$1.0M
Alan Timmins, 41 Pres, COO, Director	207K	129K
Mark Webber, 46 CFO	125K	21K
Patrick Iversen, Ph.D, 45 Senor VP of R&D	207K	--
Dwight Weller, Ph.D, 50 Sr. VP of Chemistry and Manufacturing	207K	1.8M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.

More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options

Statistics at a Glance -- NasdaqNM:AVII

As of 31-Aug-2001

Price and Volume
52-Week Low on 22-Mar-2001	$`2.906`
Recent Price	$`7.86`
52-Week High on 2-Aug-2001	$`11.00`
Beta	`0.28`
Daily Volume (3-month avg)	`112.9K`
Daily Volume (10-day avg)	`123.0K`
Stock Performance
big chart [1d \| 5d \| 3m \| 6m \| 1y \| 2y \| 5y]
52-Week Change	`-11.4%`
52-Week Change relative to S&P500	`+18.8%`
Share-Related Items
Market Capitalization	$`181.7M`
Shares Outstanding	`23.1M`
Float	`15.0M`
Dividends & Splits
Annual Dividend	none
Last Split	none

Per-Share Data
Book Value (mrq)	$`1.64`
Earnings (ttm)	-$`0.56`
Earnings (mrq)	-$`0.16`
Sales (ttm)	$`0.01`
Cash (mrq)	$`1.50`
Valuation Ratios
Price/Book (mrq)	`4.80`
Price/Earnings	N/A
Price/Sales (ttm)	`669.23`
Income Statements
Sales (ttm)	$`250.0K`
EBITDA (ttm)	-$`12.9M`
Income available to common (ttm)	-$`12.0M`
Profitability
Profit Margin	N/A
Operating Margin	N/A
Fiscal Year
Fiscal Year Ends	Dec 31
Most recent quarter	30-June-2001

Management Effectiveness
Return on Assets (ttm)	`-38.08%`
Return on Equity (ttm)	`-39.96%`
Financial Strength
Current Ratio (mrq)	`22.22`
Debt/Equity (mrq)	`0`
Total Cash (mrq)	$`34.7M`
Short Interest As of 8-Aug-2001
Shares Short	`449.0K`
Percent of Float	`3.0%`
Shares Short (Prior Month)	`524.0K`
Short Ratio	`4.49`
Daily Volume	`100.0K`

See Profile Help for a description of each item above; K = thousands; M = millions; mrq = most-recent quarter; ttm = trailing twelve months; (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.

Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.